biostudies-literatureUnknown35(24)van Geldermalsen MAlanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negativOncogene3201-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC4914826biostudies-literatureASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.PMC4914826van Geldermalsen MRitchie WHolst JRasko JEDeng NFeng YNagarajah RBeith JMO'Toole SAGao DThoeng AWang QHarvey KBailey CGMarshall ADSelinger CIfalseASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negativ2016-01-01T00:00:00Z2016 Jun2026-05-05T14:47:19.584Z2019-03-27T02:16:34ZS-EPMC49148262645532510.1038/onc.2015.381